Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Br J Pharmacol
2010 Jan 01;1592:449-61. doi: 10.1111/j.1476-5381.2009.00549.x.
Show Gene links
Show Anatomy links
Mapping the high-affinity binding domain of 5-substituted benzimidazoles to the proximal N-terminus of the GluN2B subunit of the NMDA receptor.
Wee XK
,
Ng KS
,
Leung HW
,
Cheong YP
,
Kong KH
,
Ng FM
,
Soh W
,
Lam Y
,
Low CM
.
???displayArticle.abstract???
N-methyl-D-aspartate (NMDA) receptors represent an attractive drug target for the treatment of neurological and neurodegenerative disorders associated with glutamate-induced excitotoxicity. The aim of this study was to map the binding domain of high affinity 5-substituted benzimidazole derivatives [N-{2-[(4-benzylpiperidin-1-yl)methyl]benzimidazol-5-yl}methanesulphonamide (XK1) and N-[2-(4-phenoxybenzyl)benzimidazol-5-yl]methanesulphonamide (XK2)] on the GluN2B subunit of the NMDA receptor. The pharmacological antagonistic profiles of XK1 and XK2 were assessed using in vitro rat primary cerebrocortical neurones and two-electrode voltage clamp on Xenopus oocytes expressing heterologous GluN1/GluN2B receptors. Direct ligand binding was determined using the recombinant amino-terminal domain (ATD) of GluN2B. XK1 and XK2 effectively protected against NMDA-induced excitotoxicity in rat primary cortical neurones. Low concentrations of XK1 (10 nM) and XK2 (1 nM) significantly reversed neuronal death. Both compounds failed to inhibit currents measured from oocytes heterologously expressing GluN1-1a subunit co-assembled with the ATD-deleted GluN2B subunit. XK1 and XK2 showed specific binding to recombinant protein of GluN2B ATD with low nanomolar affinities. Several residues in the recombinant ATD of GluN2B were identified to be critical for conferring XK1 and XK2 sensitivity. The inhibitory effects of XK1 and XK2 were pH-sensitive, being increased at acidic pH. These results demonstrate that XK1 and XK2 are effective neuroprotective agents in vitro and indicate that 5-substituted benzimidazole derivatives inhibit GluN1/GluN2B receptors via direct binding to the ATD of the GluN2B subunit. These compounds represent valuable alternatives to the classical antagonist ifenprodil as pharmacological tools for studying GluN2B-containing NMDA receptors.
Alexander,
Guide to Receptors and Channels (GRAC), 3rd edition.
2008, Pubmed
Alexander,
Guide to Receptors and Channels (GRAC), 3rd edition.
2008,
Pubmed
Birmingham,
Future of neuroprotective drugs in doubt.
2002,
Pubmed
Borza,
NR2B selective NMDA antagonists: the evolution of the ifenprodil-type pharmacophore.
2006,
Pubmed
Carter,
Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. II. Evidence for N-methyl-D-aspartate receptor antagonist properties.
1988,
Pubmed
Chenard,
(1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses.
1995,
Pubmed
Chenard,
Antagonists selective for NMDA receptors containing the NR2B subunit.
1999,
Pubmed
Cheng,
Emergence of excitotoxicity in cultured forebrain neurons coincides with larger glutamate-stimulated [Ca(2+)](i) increases and NMDA receptor mRNA levels.
1999,
Pubmed
Cheung,
Micromolar L-glutamate induces extensive apoptosis in an apoptotic-necrotic continuum of insult-dependent, excitotoxic injury in cultured cortical neurones.
1998,
Pubmed
Cheung,
Chronic exposure to U18666A induces apoptosis in cultured murine cortical neurons.
2004,
Pubmed
Chizh,
NMDA receptor antagonists as analgesics: focus on the NR2B subtype.
2001,
Pubmed
Collingridge,
A nomenclature for ligand-gated ion channels.
2009,
Pubmed
Dingledine,
The glutamate receptor ion channels.
1999,
Pubmed
Erreger,
Glutamate receptor gating.
2004,
Pubmed
Gitto,
Computational studies to discover a new NR2B/NMDA receptor antagonist and evaluation of pharmacological profile.
2008,
Pubmed
Gu,
Possible protection by notoginsenoside R1 against glutamate neurotoxicity mediated by N-methyl-D-aspartate receptors composed of an NR1/NR2B subunit assembly.
2009,
Pubmed
Han,
Binding of spermine and ifenprodil to a purified, soluble regulatory domain of the N-methyl-D-aspartate receptor.
2008,
Pubmed
,
Xenbase
Hartnett,
NMDA receptor-mediated neurotoxicity: a paradoxical requirement for extracellular Mg2+ in Na+/Ca2+-free solutions in rat cortical neurons in vitro.
1997,
Pubmed
Hocking,
Ketamine in chronic pain management: an evidence-based review.
2003,
Pubmed
Kambe,
Insensitivity to glutamate neurotoxicity mediated by NMDA receptors in association with delayed mitochondrial membrane potential disruption in cultured rat cortical neurons.
2008,
Pubmed
Kew,
A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones.
1996,
Pubmed
Kiss,
In vitro characterization of novel NR2B selective NMDA receptor antagonists.
2005,
Pubmed
Layton,
Recent advances in the development of NR2B subtype-selective NMDA receptor antagonists.
2006,
Pubmed
Le,
Potential and current use of N-methyl-D-aspartate (NMDA) receptor antagonists in diseases of aging.
2001,
Pubmed
Legendre,
Ifenprodil blocks N-methyl-D-aspartate receptors by a two-component mechanism.
1991,
Pubmed
Li,
Developmental changes in localization of NMDA receptor subunits in primary cultures of cortical neurons.
1998,
Pubmed
Liu,
Switching of NMDA receptor 2A and 2B subunits at thalamic and cortical synapses during early postnatal development.
2004,
Pubmed
Low,
Molecular determinants of proton-sensitive N-methyl-D-aspartate receptor gating.
2003,
Pubmed
,
Xenbase
Low,
Molecular determinants of coordinated proton and zinc inhibition of N-methyl-D-aspartate NR1/NR2A receptors.
2000,
Pubmed
,
Xenbase
Masuko,
A regulatory domain (R1-R2) in the amino terminus of the N-methyl-D-aspartate receptor: effects of spermine, protons, and ifenprodil, and structural similarity to bacterial leucine/isoleucine/valine binding protein.
1999,
Pubmed
,
Xenbase
McCauley,
NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles.
2004,
Pubmed
Mizuta,
Developmental expression of NMDA receptor subunits and the emergence of glutamate neurotoxicity in primary cultures of murine cerebral cortical neurons.
1998,
Pubmed
Mony,
Structural basis of NR2B-selective antagonist recognition by N-methyl-D-aspartate receptors.
2009,
Pubmed
,
Xenbase
Mony,
Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential.
2009,
Pubmed
Monyer,
Developmental and regional expression in the rat brain and functional properties of four NMDA receptors.
1994,
Pubmed
Mott,
Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition.
1998,
Pubmed
,
Xenbase
Murphy,
Glutamate toxicity in immature cortical neurons precedes development of glutamate receptor currents.
1990,
Pubmed
Ng,
Structural insights into phenylethanolamines high-affinity binding site in NR2B from binding and molecular modeling studies.
2008,
Pubmed
,
Xenbase
Nikam,
NR2B selective NMDA receptor antagonists.
2002,
Pubmed
Ozawa,
Cation permeability change caused by L-glutamate in cultured rat hippocampal neurons.
1988,
Pubmed
Pahk,
Influence of extracellular pH on inhibition by ifenprodil at N-methyl-D-aspartate receptors in Xenopus oocytes.
1997,
Pubmed
,
Xenbase
Paoletti,
NMDA receptor subunits: function and pharmacology.
2007,
Pubmed
Perin-Dureau,
Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors.
2002,
Pubmed
,
Xenbase
Pinard,
4-Aminoquinolines as a novel class of NR1/2B subtype selective NMDA receptor antagonists.
2002,
Pubmed
Portera-Cailliau,
N-methyl-D-aspartate receptor proteins NR2A and NR2B are differentially distributed in the developing rat central nervous system as revealed by subunit-specific antibodies.
1996,
Pubmed
Reisberg,
Memantine in moderate-to-severe Alzheimer's disease.
2003,
Pubmed
Rosahl,
A genetically modified mouse model probing the selective action of ifenprodil at the N-methyl-D-aspartate type 2B receptor.
2006,
Pubmed
,
Xenbase
Sans,
A developmental change in NMDA receptor-associated proteins at hippocampal synapses.
2000,
Pubmed
Schoemaker,
Binding of [3H]ifenprodil, a novel NMDA antagonist, to a polyamine-sensitive site in the rat cerebral cortex.
1990,
Pubmed
Sheng,
Changing subunit composition of heteromeric NMDA receptors during development of rat cortex.
1994,
Pubmed
Traynelis,
Control of voltage-independent zinc inhibition of NMDA receptors by the NR1 subunit.
1998,
Pubmed
,
Xenbase
Wamil,
Use-, concentration- and voltage-dependent limitation by MK-801 of action potential firing frequency in mouse central neurons in cell culture.
1992,
Pubmed
Wee,
Immunolocalization of NMDA receptor subunit NR3B in selected structures in the rat forebrain, cerebellum, and lumbar spinal cord.
2008,
Pubmed
Williams,
Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors.
1993,
Pubmed
,
Xenbase
Williams,
Ifenprodil, a novel NMDA receptor antagonist: site and mechanism of action.
2001,
Pubmed
Witt,
Memantine hydrochloride.
2004,
Pubmed
Wong,
Expression and characterization of soluble amino-terminal domain of NR2B subunit of N-methyl-D-aspartate receptor.
2005,
Pubmed
Ying,
Assessment of cell viability in primary neuronal cultures.
2001,
Pubmed
Yuan,
Conserved structural and functional control of N-methyl-D-aspartate receptor gating by transmembrane domain M3.
2005,
Pubmed
Yuen,
Postsynaptic density-95 (PSD-95) and calcineurin control the sensitivity of N-methyl-D-aspartate receptors to calpain cleavage in cortical neurons.
2008,
Pubmed
Zheng,
Allosteric interaction between the amino terminal domain and the ligand binding domain of NR2A.
2001,
Pubmed